(TheNewswire)
VANCOUVER, BC - TheNewswire - October 28, 2022 - AREV Life Sciences Global Corp. (CSE:AREV)(OTC:AREVF) (“AREV” or the “Company”) ispleased to announce the appointment of Dr. Andrew Levinson to thecompany’s Scientific Advisory Board. Dr. Levinson is dedicated toprogressive direction in integrative health, Dr. Levinson is afunctional medicine doctor and psychiatrist combining mainstream andalternative approaches together with comprehensive treatments. He hasdeveloped and commercialized a line of complementary products brandedas “Vitality Health and Wellness” which he sells though hisclinics and concierge service. The line addresses nutrition andholistic deficiencies in patients.
Dr. Levinson received both his Bachelor of Science inPsychobiology and his Medical Doctorate from University of Miami.While at University of Miami, in 1993 Dr. Levinson created and chairedan alternative medicine conference which was integrated into themedical school’s curriculum for both students and professors. Healso pursued academia as an Assistant Professor in the Department ofPsychiatry at Florida International University’s College ofMedicine. Dr. Levinson has affiliation with; the International AIDS Society (IAS), the InternationalAssociation of Providers of AIDS Care (IAPAC), the American Academy of HIVMedicine (AAHIVM), and the Infectious Disease Society of America (IDSA).
Following data presented at The 24 th InternationalAIDS conference (AIDS 2022) in Montreal this past July whichdemonstrates the significant impact of neuropsychiatric complicationsof Serious Acute Malnutrition (SAM) both compounded by andexacerbating HIV Associated Neurological Disorder (HAND), AREV LifeSciences expands the capacities of its Scientific AdvisoryBoard.
Clinical research has demonstrated the necessity ofaffording comprehensive psychiatric evaluations as an essential component of our clinical studies in pediatric populationsexperiencing SAM,” said Dr. Sateesh Apte, neurologist and AREVScientific Advisory Board Member. “The psychiatric implications ofSAM in pediatric populations is obviously a driving concern inaddressing the devastating consequences of neurodegeneration but thismorbid condition remains wholly unaddressed in the literature. AREV iscommitted to developing SUSTAINN™ in studies that complementthe development of global agendas on mental health and food securityand nutrition.
“AREV is enthusiastic about the addition of Dr.Levinson and his extensive experience in integrative psychiatry as wework to bring products to market within lower-to-middle-incomecountries (LMICs) as well as our wellness categories of therapeuticnutrition” said AREV Chairman and CEO Mike Withrow. The evolution ofAREV’s clinical nutrition pipeline, including our enteral formulaRe-Store™ and SUSTAINN™, our next generation ready-to-usetherapeutic food (RUTF).
“The collective psychiatric impact of SAM obviouslyis accompanied by pediatric trauma of egregious proportion with amultitude of studies showing associations between poor mental healthand malnutrition, low intake of certain nutrients and Body MassIndex” said Dr. Levinson. “ AREV’s development of SUSTAINN™ isproviding the psychiatric community insight into the appropriateclinical management of tens of millions of patients the throughoutresource-challenged nations at a historical point when famine and foodinsecurity is affecting the survival as well the cognitive developmentof children in Asia, Africa, the Middle East, and Pacific Islandnations.”
AREV’s initial concept sheets which are beingsubmitted to publicly sponsored clinical research networks, that arecorresponding with public health commodity procurement programs, isintended to demonstrate the superiority of SUSTAINN™ in clinicaltrials measuring its efficacy against standard of care for addressingSAM in pediatric populations in LMIC settings. The United NationsInternational Children’s Emergency Fund (UNICEF) procures anestimated 75- 80 per cent of the global demand for RUTF, averaging49,000 metric tons (MT) per year over the last four years, suitable totreat 3.5 million children. The Global Nutrition report in 2017 made aclear case
for the importance of improving nutrition in achievingat least five Sustainable Development Goals (SDG) of the UN'sDevelopment Agenda. (source: https://www.unicef.org/supply/media/7256/file/RUTF-Supply-Update-March-2021.pdf )
AREV Scientific Advisory Board Chairman and formerUnited States Assistant Surgeon General Roscoe Moore, DVM, MPH, PhD,said “Dr Levenson’s appointment expands AREV’s capacity tobetter design our clinical studies on SUSTAINN™ in LMIC pediatricpatient populations vulnerable to cognitive damage due to seriousacute malnutrition, being launched in coordination with our academicand industry partners”.
About SUSTAINN ™ , AREV’sReady-to-Use Therapeutic Food (RUTF)
SUSTAINN™ (Superior Utility Supplementation Therapeutic Agent forIndicated Nutritional Needs) is a next generation RUTF being developedby AREV Life Sciences, based in Vancouver. This initiative aims todemonstrate the delivery of measurable therapeutic effect in forthcoming inferiority/superiority studies througha unique next-generation RUTF composition. SUSTAINN™ is intended totreat inanition, the complex disease state that is currently theculprit in the deaths of nine million people worldwide annually, morethan the death toll of AIDS, malaria, and tuberculosis combined.Inanition is clinically characterized by dysbiosis, environmentalenteropathy, neurodegenerative disease, organ failure, scurvy,beriberi, Kwashiorkor, and anemia due to SAM.
SUSTAINN™ is being developed in collaboration withThe Richardson Centre for Food Technology and Research, University ofManitoba, TransBiotech, and key opinion leaders in biology,therapeutic development and clinical study design from the Instituteof Human Virology, University of Maryland and The Linus Pauling Centerat Oregon State University, is in compliance with WHO, andCodex-Alimentarious guidelines in 43 countries. RUTF’s are essentialtherapeutic interventions for the treatment of severe acutemalnutrition and currently account for more than US $440M in 2022 insales by more than 40 companies. SUSTAINN™ is being produced underGMP conditions, which meet relevant export criteria, is aflatoxin freeand designed to maintain a shelf life of up to two years underappropriate storage instructions. SUSTAINN™ provides optimalnutritional support addressing the restoration of gut microbiota,malabsorption associated with cachexia, provides essential nutrition,vitamins, minerals and protein that encourage muscle retention, andmetabolic functions including ATP levels and EFA supplementation thatencourages neurological development. Further collaborations are indevelopment following meetings at AIDS 2022 with AREV Executiveleadership and key opinion leaders in positions of program leadershipat PEPFAR, the Global Fund for AIDS TB and Malaria, UNAIDS USAID andthe World Food Program.
Further, the Company is pleased to announce that theCompany has issued 100,000 stock options to Directors, Officers andConsultants of the Company at a price of $0.12 for a period of 5 yearsfrom the issuance dated. These options will vest immediately.
AREV Life Sciences Global Corporation also announcestoday the resignation of Kevin Phelps as COO and the settlement ofdebt with Nava Financial Inc.
The Company announces the resignation of Mr. KevinPhelps as Chief Operating Officer (“COO”) of the Company. Mr.Phelps feels that the Company is at a critical step in itsdevelopment, and onsite leadership is needed at this time. Due to Mr.Phelps being located in New York, and given the challenges ofInternational travel given the pandemic, he was no longer the best fitfor this role. Mr. Phelps will continue on as a member of the Board ofDirectors of the Company. The Company would like to thank Mr. Phelpsfor his efforts at COO.
The Company is also pleased toannounce it has settled $9,000 in debt with Nava Financial Inc., bythe issuance of 75,000 Shares at $0.12.
For further information, contact Mike Withrow,mike@AREVBrands.com 778-929-6536. For more informationvisit https://www.arevlifesciences.com/.
On behalf of the Board,
Mike Withrow
CEO & Director
AboutAREV Life Sciences Global Corp.
The Company is a fully integrated enterprise withcompetencies in: 1) extraction of compounds for consumption andtopical use. 2) Clinical Nutrition and 3) A technology platform calledMedicine Merchant. The Company produces ingredients and formulatesexclusive therapeutic interventions with plans to deliver innovationin clinical nutrition, proprietary supplements, topicals and rationaldrug design, based on science. The Company’s business modelleverages its core competency of extraction to produce ingredients andcompounds for its pipeline of products. The Company continues in theproduct development and pre-commercialization stage.
AREV is dedicated to designing and deliveringinnovation in rational drug design, driven by presenting globalepidemiological characteristics of multiple challenges tointernational human and animal health. AREV is a member of bothBIOTECanada and The Biotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITSREGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITYFOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in policies ofthe CSE) accepts responsibility for the adequacy or accuracy of thisrelease. This news release may includeforward-looking statements that are subject to risks anduncertainties. All statements within, other than statements ofhistorical fact, are to be considered forward looking. Although theCompany believes the expectations expressed in such forward lookingstatements are based on reasonable assumptions, such statements arenot guarantees of future performance and actual results ordevelopments may differ materially from those in forward-lookingstatements. Factors that could cause actual results to differmaterially from those in forward-looking statements include marketprices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as required
under the applicable laws. This press release containsforward-looking statements. The use of any of the words"anticipate", "continue", "estimate","expect", "may", "will","project", "should", "believe" andsimilar expressions are intended to identify forward-lookingstatements. Although the Company believes that the expectations andassumptions on which the forward-looking statements are based arereasonable, undue reliance should not be placed on the forward-lookingstatements because the Company can give no assurance that they willprove to be correct. Since forward-looking statements
address future events and conditions, by their verynature they involve inherent risks and uncertainties. These statementsspeak only as of the date of this press release. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks various risk factors discussed in theCompany’ s Management ’sDiscussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2022 TheNewswire - All rights reserved.